Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy

• DOI: 10.1038/ncomms11221
• Publication Date: 2016-04-13T11:32:42Z
• Authors: Yiming Zhao; François Fay; Sjoerd Hak; Jose Manuel Perez...; Brenda L. Sanchez...; Brandon Goode; Raphaël Duivenvoo...; Catharina de Lang...; Astrid Bjørkøy; Harel Weinstein; Zahi A. Fayad; Carlos Pérez-Medina; Willem J. M. Mulder
• Keywords: Nanocarriers; Nanocapsules; Targeted drug delivery

Abstract A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery anti-tumour agents. The drug–carrier association after intravenous administration essential efficient drug the tumour. However, a large number currently available nanocarriers are self-assembled whose drug-loading stability critically affected by in vivo environment. Here we used FRET imaging systematically investigate how compatibility affects release tumour mouse model. We found drug’s hydrophobicity and miscibility with two independent key parameters that determine its accumulation Next, applied these findings improve chemotherapeutic augmenting parent compatibility; result, achieved better antitumour efficacy. Our results help elucidate nanomedicines’ fate provide guidelines delivery.